Search
Search
Mark Gillies, MD, PhD
Show Description +
Professor Gillies explores CRVO management and discusses significant developments, such as the introduction of surgical intervention, intravitreal steroids, and the possibility of anti-VEGFs and anti-angiogetic treatment, which are proving to offer significantly better outcomes. He discusses the core CRVO anti-VEGF studies, COPERNICUS, GALILEO, CRUISE and HORIZON, their study designs and the key efficacy and safety outcomes that have been demonstrated across these studies of aflibercept and ranibizumab. Whilst it is important to start CRVO treatment early in order to maximise clinical benefit and prevent vision loss, each patient should be treated as an individual. In response to this, the Treat and Extend optimal treatment regimen was developed and is now part of the EYLEA label in Europe.
Posted: 9/29/2015
Mark Gillies, MD, PhD
Professor Gillies explores CRVO management and discusses significant developments, such as the introduction of surgical intervention, intravitreal steroids, and the possibility of anti-VEGFs and anti-angiogetic treatment, which are proving to offer significantly better outcomes. He discusses the core CRVO anti-VEGF studies, COPERNICUS, GALILEO, CRUISE and HORIZON, their study designs and the key efficacy and safety outcomes that have been demonstrated across these studies of aflibercept and ranibizumab. Whilst it is important to start CRVO treatment early in order to maximise clinical benefit and prevent vision loss, each patient should be treated as an individual. In response to this, the Treat and Extend optimal treatment regimen was developed and is now part of the EYLEA label in Europe.
Posted: 9/29/2015
Please log in to leave a comment.